Related Experiment Video
Updated: Aug 8, 2026
Ex Vivo Perfusion of the Rodent Placenta
Published on: May 30, 2019
Placental transfer of rosiglitazone in the ex vivo human perfusion model
Heather J Holmes1, Brian M Casey, Roger E Bawdon
1Department of Obstetrics and Gynecology, University of Texas Southwestern Medical Center at Dallas, Dallas, TX, USA.
Objective:
The objective of the study was to determine transplacental passage of rosiglitazone (Avandia) using the ex vivo human placental model.
Study Design:
Perfusion studies were performed on 10 placentas from term, uncomplicated deliveries. Concentrations typical for an 8-mg oral dose (216 to 692 ng/mL) as well as 2- to 3-fold increased concentrations were tested (734 to 1261 ng/mL). Transfer of rosiglitazone was assessed and accumulation was determined using the 14C-antipyrine reference method.
Results:
The clearance index for low and high concentrations were 0.14 +/- 0.04 and 0.20 +/- 0.08, suggesting that the drug passes through the placenta at a relatively low rate. Fetal accumulation occurred in only 1 of 5 placentas at 16.4 ng/mL (5%) for the 8-mg dose and in 2 of 5 placentas ranging from 0 to 74 ng/mL (5% to 8%) at higher concentrations.
Conclusion:
There is minimal transfer and fetal accumulation of rosiglitazone according to the ex vivo human perfusion model.
More Related Videos
08:08Determination of the Transport Rate of Xenobiotics and Nanomaterials Across the Placenta using the ex vivo Human Placental Perfusion Model
Published on: June 18, 2013
06:08Semi-Automated Isolation of the Stromal Vascular Fraction from Murine White Adipose Tissue Using a Tissue Dissociator
Published on: May 19, 2023